CR20120127A - Anticuerpos monoclonales - Google Patents
Anticuerpos monoclonalesInfo
- Publication number
- CR20120127A CR20120127A CR20120127A CR20120127A CR20120127A CR 20120127 A CR20120127 A CR 20120127A CR 20120127 A CR20120127 A CR 20120127A CR 20120127 A CR20120127 A CR 20120127A CR 20120127 A CR20120127 A CR 20120127A
- Authority
- CR
- Costa Rica
- Prior art keywords
- monoclonal antibodies
- fibrinogen
- fibrin
- domain
- inhibits
- Prior art date
Links
- 102000009123 Fibrin Human genes 0.000 abstract 3
- 108010073385 Fibrin Proteins 0.000 abstract 3
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 abstract 3
- 102000008946 Fibrinogen Human genes 0.000 abstract 3
- 108010049003 Fibrinogen Proteins 0.000 abstract 3
- 229950003499 fibrin Drugs 0.000 abstract 3
- 229940012952 fibrinogen Drugs 0.000 abstract 3
- 101100289995 Caenorhabditis elegans mac-1 gene Proteins 0.000 abstract 1
- 230000002025 microglial effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Heart & Thoracic Surgery (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Physical Education & Sports Medicine (AREA)
- Transplantation (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
La presente invención provee un anticuerpo aislado que se une al dominio YC de fibrina o fibrinógeno. en varios aspectos, el anticuerpo inhibe la adhesión microglial al dominio YC de fibrina o fibrinógeno, inhibe la unión del Mac-1 al dominio YC de fibrina o fibrinógeno.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US24801409P | 2009-10-02 | 2009-10-02 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CR20120127A true CR20120127A (es) | 2012-05-28 |
Family
ID=43826649
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CR20120127A CR20120127A (es) | 2009-10-02 | 2012-03-16 | Anticuerpos monoclonales |
Country Status (38)
| Country | Link |
|---|---|
| US (1) | US8877195B2 (es) |
| EP (1) | EP2483416B1 (es) |
| JP (1) | JP5883389B2 (es) |
| KR (1) | KR101793221B1 (es) |
| CN (1) | CN102575277B (es) |
| AR (1) | AR078490A1 (es) |
| AU (1) | AU2010300559B2 (es) |
| BR (1) | BR112012008370B8 (es) |
| CA (1) | CA2774256C (es) |
| CL (1) | CL2012000788A1 (es) |
| CO (1) | CO6440561A2 (es) |
| CR (1) | CR20120127A (es) |
| CY (1) | CY1118540T1 (es) |
| DK (1) | DK2483416T3 (es) |
| DO (1) | DOP2012000089A (es) |
| EA (1) | EA023477B1 (es) |
| ES (1) | ES2614939T3 (es) |
| GE (2) | GEP20156214B (es) |
| GT (1) | GT201200096A (es) |
| HR (1) | HRP20170110T1 (es) |
| HU (1) | HUE031571T2 (es) |
| IL (1) | IL218621B (es) |
| IN (1) | IN2012DN03154A (es) |
| LT (1) | LT2483416T (es) |
| MA (1) | MA33704B1 (es) |
| MX (1) | MX2012003811A (es) |
| MY (1) | MY159359A (es) |
| NZ (1) | NZ598770A (es) |
| PH (1) | PH12012500551A1 (es) |
| PL (1) | PL2483416T3 (es) |
| PT (1) | PT2483416T (es) |
| SI (1) | SI2483416T1 (es) |
| SM (2) | SMT201700083T1 (es) |
| TN (1) | TN2012000149A1 (es) |
| TW (1) | TWI511741B (es) |
| UA (1) | UA108860C2 (es) |
| WO (1) | WO2011041518A1 (es) |
| ZA (1) | ZA201202227B (es) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8771693B2 (en) | 2009-10-27 | 2014-07-08 | Beth Israel Deaconess Medical Center, Inc. | Methods and compositions for the generation and use of conformation-specific antibodies |
| US10485780B2 (en) | 2011-03-14 | 2019-11-26 | Beth Israel Deaconess Medical Center, Inc. | Methods and compositions for the treatment of proliferative disorders |
| WO2012149334A2 (en) | 2011-04-27 | 2012-11-01 | Beth Israel Deaconess Medical Center, Inc. | Methods and compositions for the generation and use of conformation-specific antibodies |
| WO2012162698A1 (en) | 2011-05-26 | 2012-11-29 | Beth Israel Deaconess Medical Center, Inc. | Methods and compositions for the treatment of immune disorders |
| AU2013271378A1 (en) | 2012-06-07 | 2014-12-18 | Beth Israel Deaconess Medical Center, Inc. | Methods and compositions for the inhibition of Pin1 |
| US9688747B2 (en) | 2013-03-15 | 2017-06-27 | Beth Israel Deaconess Medical Center, Inc. | Methods and compositions for the generation and use of conformation-specific antibodies |
| US10451611B2 (en) | 2014-01-11 | 2019-10-22 | The J. David Gladstone Institute | Compositions and methods for in vitro assays of fibrin activity |
| WO2016011265A2 (en) | 2014-07-17 | 2016-01-21 | Beth Israel Deaconess Medical Center, Inc. | Biomarkers for pin1-associated disorders |
| WO2016011268A1 (en) | 2014-07-17 | 2016-01-21 | Beth Israel Deaconess Medical Center, Inc. | Atra for modulating pin1 activity and stability |
| US10548864B2 (en) | 2015-03-12 | 2020-02-04 | Beth Israel Deaconess Medical Center, Inc. | Enhanced ATRA-related compounds for the treatment of proliferative diseases, autoimmune diseases, and addiction conditions |
| BR112019022643A2 (pt) * | 2017-05-02 | 2020-05-19 | Nat Cancer Center Japan | conjugado de fármaco-anticorpo anti-fibrina insolúvel clivável por plasmina |
| EP4130269A4 (en) * | 2020-03-31 | 2024-03-06 | National Cancer Center | Fibrin-binding antibody and pharmaceutical composition containing antibody |
| EP4262870A4 (en) * | 2020-12-16 | 2024-10-30 | The J. David Gladstone Institutes, A Testamentary Trust Established under The Will of J. David Gladstone | USE OF FIBRIN-TARGETED IMMUNOTHERAPY TO REDUCE CORONAVIRUS PATHOGENESIS |
| WO2022159776A1 (en) * | 2021-01-21 | 2022-07-28 | Therini Bio, Inc. | Antibodies which bind human fibrin and methods of use |
| EP4355772A2 (en) * | 2021-06-18 | 2024-04-24 | Therini Bio, Inc. | Antibodies which bind human fibrin or fibrinogen ?c domain and methods of use |
| KR20240049265A (ko) * | 2021-06-18 | 2024-04-16 | 테리니 바이오, 인코포레이티드 | 인간 피브린 또는 피브리노겐 γC 도메인에 결합하는 항체 및 사용 방법 |
| EP4577566A1 (en) * | 2022-08-22 | 2025-07-02 | The J. David Gladstone Institutes, A Testamentary Trust Established under The Will of J. David Gladstone | Human anti-fibrin antibodies and uses thereof |
| WO2024191900A2 (en) * | 2023-03-10 | 2024-09-19 | The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone | Methods and compositions for cellular immunotherapy – fib4 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030031675A1 (en) * | 2000-06-06 | 2003-02-13 | Mikesell Glen E. | B7-related nucleic acids and polypeptides useful for immunomodulation |
| PT2314621E (pt) * | 2004-05-27 | 2014-06-23 | Crucell Holland Bv | Moléculas de ligação capazes de neutralizar o vírus da raiva, e suas utilizações |
| US7807645B2 (en) * | 2005-09-23 | 2010-10-05 | The Regents Of The University Of California | Method of treating degenerative disorders of the nervous system by administration of fibrinogen fragment |
-
2010
- 2010-09-30 BR BR112012008370A patent/BR112012008370B8/pt active IP Right Grant
- 2010-09-30 EA EA201270416A patent/EA023477B1/ru unknown
- 2010-09-30 ES ES10821238.2T patent/ES2614939T3/es active Active
- 2010-09-30 DK DK10821238.2T patent/DK2483416T3/en active
- 2010-09-30 MX MX2012003811A patent/MX2012003811A/es active IP Right Grant
- 2010-09-30 SM SM20170083T patent/SMT201700083T1/it unknown
- 2010-09-30 UA UAA201203044A patent/UA108860C2/ru unknown
- 2010-09-30 LT LTEP10821238.2T patent/LT2483416T/lt unknown
- 2010-09-30 HU HUE10821238A patent/HUE031571T2/en unknown
- 2010-09-30 SI SI201031390A patent/SI2483416T1/sl unknown
- 2010-09-30 PT PT108212382T patent/PT2483416T/pt unknown
- 2010-09-30 GE GEAP201012676A patent/GEP20156214B/en unknown
- 2010-09-30 HR HRP20170110TT patent/HRP20170110T1/hr unknown
- 2010-09-30 MY MYPI2012001408A patent/MY159359A/en unknown
- 2010-09-30 KR KR1020127011293A patent/KR101793221B1/ko not_active Expired - Fee Related
- 2010-09-30 GE GEAP201013232A patent/GEP20166458B/en unknown
- 2010-09-30 NZ NZ598770A patent/NZ598770A/en unknown
- 2010-09-30 WO PCT/US2010/050873 patent/WO2011041518A1/en active Application Filing
- 2010-09-30 JP JP2012532307A patent/JP5883389B2/ja active Active
- 2010-09-30 EP EP10821238.2A patent/EP2483416B1/en active Active
- 2010-09-30 CA CA2774256A patent/CA2774256C/en active Active
- 2010-09-30 AU AU2010300559A patent/AU2010300559B2/en active Active
- 2010-09-30 PH PH1/2012/500551A patent/PH12012500551A1/en unknown
- 2010-09-30 PL PL10821238T patent/PL2483416T3/pl unknown
- 2010-09-30 CN CN201080046037.8A patent/CN102575277B/zh active Active
- 2010-10-01 TW TW099133559A patent/TWI511741B/zh active
- 2010-10-01 AR ARP100103578A patent/AR078490A1/es not_active Application Discontinuation
-
2012
- 2012-03-14 IL IL218621A patent/IL218621B/en not_active IP Right Cessation
- 2012-03-16 CR CR20120127A patent/CR20120127A/es unknown
- 2012-03-20 US US13/425,020 patent/US8877195B2/en active Active
- 2012-03-27 ZA ZA2012/02227A patent/ZA201202227B/en unknown
- 2012-03-29 DO DO2012000089A patent/DOP2012000089A/es unknown
- 2012-03-30 CL CL2012000788A patent/CL2012000788A1/es unknown
- 2012-03-30 TN TNP2012000149A patent/TN2012000149A1/en unknown
- 2012-03-30 GT GT201200096A patent/GT201200096A/es unknown
- 2012-04-12 IN IN3154DEN2012 patent/IN2012DN03154A/en unknown
- 2012-04-18 CO CO12064155A patent/CO6440561A2/es active IP Right Grant
- 2012-04-30 MA MA34824A patent/MA33704B1/fr unknown
-
2017
- 2017-01-30 CY CY20171100132T patent/CY1118540T1/el unknown
- 2017-02-08 SM SM201700083T patent/SMT201700083B/it unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CR20120127A (es) | Anticuerpos monoclonales | |
| ECSP14013307A (es) | Genzyme corporation | |
| UA106070C2 (uk) | Антитіло, що специфічно зв'язується з egfr і her3 | |
| CY1116488T1 (el) | Αντισωματα anti-προπερδινης | |
| CL2011002306A1 (es) | Anticuerpo o un fragmento de union a antigeno del mismo que se une especificamente a la integrina heterodimero alfa4beta7; y composicion que lo comprende. | |
| CR20170383A (es) | Anticuerpos anti-cd3, anticuerpos anti-cd-123 y anticuerpos biespecíficos que se unen específicamente a cd3 y/o cd123 | |
| MX2009004532A (es) | Composiciones y metodos para unir esfingosina-1-fosfato. | |
| TR201904088T4 (tr) | Anti-CGRP bileşimleri ve bunların kullanımları. | |
| MX384225B (es) | ANTICUERPOS IgG BIESPECIFICOS, ACOPLADORES DE LINFOCITOS T. | |
| EA201100300A1 (ru) | Композиции и способы, предназначенные для направленного воздействия антител на белок c5 системы комплемента | |
| CL2012000254A1 (es) | Anticuerpo aislado de unión a antígeno que se une a proteína atenuante de linfocitos b y t (btla); ácido nucleico que lo codifica; composición que comprende a dicho anticuerpo; y vector de expresión. | |
| MX373426B (es) | Moleculas de enlace a il-18. | |
| CY1121167T1 (el) | Βελτιωμενα αντισωματα εναντι της ανθρωπινης φρακταλκινης και χρησεις αυτων | |
| GT200600186A (es) | Agentes de unión | |
| NZ602294A (en) | Monoclonal antibodies against c-met | |
| MX374826B (es) | Un anticuerpo biespecífico que se une a pcrv y psl de pseudomonas. | |
| UA113879C2 (xx) | ГУМАНІЗОВАНЕ АНТИТІЛО ПРОТИ ТrkА З АМІНОКИСЛОТНИМИ ЗАМІЩЕННЯМИ | |
| CR20110559A (es) | Anticuerpos específicos para cadherina-17 | |
| CY1118420T1 (el) | Αντι-ιδιοτυπικο αντισωμα εναντι ενος αντισωματος εναντι του βητα αμυλοειδους πεπτιδιου | |
| MA35740B1 (fr) | Compositions et procédés pour des anticorps ciblant le facteur p | |
| EA201291065A1 (ru) | Антитела против vla-4 | |
| TR201819828T4 (tr) | Anti-fosfolipaz d4 antikoru. | |
| GT201200266A (es) | Anticuerpos il-25 humanizados | |
| CO2017004753A2 (es) | Anticuerpos que se unen a ccr6 | |
| EA201992316A1 (ru) | Композиции и способы для диагностики рака предстательной железы |